These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34534639)

  • 1. miRNAs and androgen deprivation therapy for prostate cancer.
    Konoshenko MY; Bryzgunova OE; Laktionov PP
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188625. PubMed ID: 34534639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
    Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
    Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
    O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
    Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent androgen deprivation therapy in advanced prostate cancer.
    Alva A; Hussain M
    Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis.
    Zhang Y; Zhao J; Ding M; Su Y; Cui D; Jiang C; Zhao S; Jia G; Wang X; Ruan Y; Jing Y; Xia S; Han B
    J Exp Clin Cancer Res; 2020 Dec; 39(1):282. PubMed ID: 33317606
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Alzoubi A; Al Bashir S; Smairat A; Alrawashdeh A; Haddad H; Kheirallah K
    J Med Life; 2023 Apr; 16(4):593-598. PubMed ID: 37305830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer therapy outcome prediction: are miRNAs a suitable guide for therapeutic decisions?
    Konoshenko M; Laktionov P; Bryzgunova O
    Andrology; 2024 May; 12(4):705-718. PubMed ID: 37750354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance.
    Ottman R; Nguyen C; Lorch R; Chakrabarti R
    Mol Cancer; 2014 Jan; 13():1. PubMed ID: 24387052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy.
    Al-Janabi H; Moyes K; Allen R; Fisher M; Crespo M; Gurel B; Rescigno P; de Bono J; Nunns H; Bailey C; Junker-Jensen A; Muthana M; Phillips WA; Pearson HB; Taplin ME; Brown JE; Lewis CE
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
    Ji G; Song G; Huang C; He S; Zhou L
    Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
    Wang Y; Dai B; Ye DW
    Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy.
    Shibata Y; Suzuki K; Arai S; Miyoshi Y; Umemoto S; Masumori N; Kamiya N; Ichikawa T; Kitagawa Y; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Kubota Y
    Andrology; 2013 May; 1(3):505-11. PubMed ID: 23444052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.
    Edlind MP; Hsieh AC
    Asian J Androl; 2014; 16(3):378-86. PubMed ID: 24759575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A
    Toren P; Hoffman A; Ding K; Joncas FH; Turcotte V; Caron P; Pouliot F; Fradet Y; Lévesque É; Guillemette C; Klotz L
    Clin Cancer Res; 2018 Nov; 24(21):5305-5312. PubMed ID: 30021911
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.